Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, November 27, 2024
[ 07:40 PM ] - Thomas Matters
[ 05:41 PM ] - Thomas Matters
[ 05:40 PM ] - Thomas Matters
[ 05:40 PM ] - Thomas Matters
[ 05:21 PM ] - Thomas Matters
[ 05:20 PM ] - Thomas Matters
[ 05:03 PM ] - Thomas Matters
[ 05:03 PM ] - Thomas Matters
[ 05:03 PM ] - Thomas Matters
[ 05:02 PM ] - Thomas Matters
[ 05:02 PM ] - Thomas Matters
[ 05:02 PM ] - Thomas Matters
[ 05:02 PM ] - Thomas Matters
[ 05:01 PM ] - Thomas Matters
[ 05:01 PM ] - Thomas Matters
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
- Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more on ARWR stock here.
The article from Seeking Alpha discusses Arrowhead Pharmaceuticals' recent partnership with Sarepta Therapeutics, which has validated Arrowhead's RNA interference (RNAi) platform. This collaboration focuses on developing treatments for Duchenne muscular dystrophy (DMD) using Arrowhead's RNAi technology. The partnership not only reduces the financial risk for Arrowhead by providing a significant upfront payment and potential milestone payments but also enhances the credibility of Arrowhead's technology in the biotech industry. The deal includes an exclusive license for Sarepta to use Arrowhead's RNAi technology for DMD, with Arrowhead receiving $150 million upfront and potential for up to $1.6 billion in milestone payments plus royalties. This move is seen as a strategic step for Arrowhead to leverage its platform in a high-value therapeutic area, potentially accelerating the development of new treatments while sharing the financial burden and risk with Sarepta.
Read the Full Seeking Alpha Article at [ https://seekingalpha.com/article/4740766-arrowhead-the-sarepta-partnership-validates-rnai-platform-and-reduces-risk ]
Read the Full Seeking Alpha Article at [ https://seekingalpha.com/article/4740766-arrowhead-the-sarepta-partnership-validates-rnai-platform-and-reduces-risk ]
